Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV001078933 | SCV003853558 | benign | Angelman syndrome | 2022-12-08 | reviewed by expert panel | curation | The allele frequency of the p.Phe426= variant in UBE3A (NM_130838.2) is 0.014% in European (non-Finnish) sub population in gnomAD, which is high enough to meet the BS1 criteria based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BS1). The p.Phe426= variant is not predicted to affect splicing using multiple computational tools and does not affect a highly conserved nucleotide (BP7). In summary, the p.Phe426= variant in UBE3A (NM_130838.2) is classified as Likely Benign based on the ACMG/AMP criteria (BS1, BP7). |
Eurofins Ntd Llc |
RCV000724495 | SCV000229250 | uncertain significance | not provided | 2015-02-19 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000724495 | SCV000515222 | likely benign | not provided | 2020-04-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001078933 | SCV001009840 | likely benign | Angelman syndrome | 2024-01-19 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000724495 | SCV001748437 | likely benign | not provided | 2021-06-01 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002372091 | SCV002686991 | likely benign | Inborn genetic diseases | 2020-03-12 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |